Presentation

Company Profile
Egetis Therapeutics is a Swedish pharmaceutical company focusing rare diseases. The lead program Emcitate is intended for the treatment of a rare but severely life-impairing and life-shortening genetic disease, called MCT8 deficiency. The second program, aladote, is being developed against acute liver failure due to paracetamol poisoning. The third asset, pledOx, stopped under the company’s previous name (PledPharma) is being further developed by the Asian partner Solasia. The firm was founded in 2006 (as PledPharma) and changed its name to Egetis Therapeutics upon the merger with Rare Thyroid Therapeutics in 2020.

Recent highlights
The company has been progressing its lead asset Emcitate in its pivotal trial despite the COVID-19 pandemic. However, the second asset, aladote, which finds its use in the acute ward (paracetamol poisoning), has understandably been delayed by the pandemic and has yet to start its pivotal trial.

Outlook
We expect full enrolment of emcitate’s pivotal trial by end of year with an interim update later in 2022. Aladote’s pivotal trial is scheduled to start as well before end of year.